- Enlivex Therapeutics (ENLV, Financial) to present Allocetra data at OARSI 2025 World Congress.
- Studies show promising results in safety, pain reduction, and joint function improvement.
- Allocetra helps patients avoid knee replacement surgery.
Enlivex Therapeutics (Nasdaq: ENLV) is set to present promising data on its cell therapy product, Allocetra™, at the Osteoarthritis Research Society International (OARSI) 2025 World Congress in Incheon, South Korea, from April 24-27, 2025. The company plans to highlight the potential of Allocetra™ in treating osteoarthritis through two distinct poster presentations.
The presentations will feature results from both preclinical studies and Phase I/II clinical trials. The trials demonstrated that Allocetra™, an off-the-shelf macrophage reprogramming cell therapy, showed significant results including favorable safety profiles, substantial pain reduction, and improved joint function in patients with moderate to end-stage osteoarthritis. Notably, some patients were able to avoid knee replacement surgery, indicating potential disease-modifying properties.
Two presentations are scheduled during the conference: a Flash Talk & Poster presentation on Phase I/II clinical trial results (Abstract #092), and a Poster presentation on Allocetra's biological activity in preclinical models (Abstract #4231304). Enlivex's CEO, Dr. Oren Hershkovitz, and CMO, Dr. Einat Galamidi, will be available for discussions and meetings throughout the event.
Enlivex's Allocetra™ works by reprogramming macrophages to achieve immune homeostasis in joint tissues, potentially addressing the root causes of osteoarthritis rather than simply managing symptoms. While these initial findings are encouraging, Enlivex continues to pursue larger confirmatory trials to further validate Allocetra's clinical benefits.
